Elamipretide (SS-31): What the Published Mitochondrial Research Reports

Elamipretide, also designated SS-31, MTP-131 or Bendavia, is described in a narrative review as a synthetic tetrapeptide whose structure permits uptake into a variety of cell types and selective localisation to mitochondria, where it is reported to bind cardiolipin in the inner mitochondrial membrane and to be associated with cristae stabilisation, reduced oxidative stress and altered ATP production in preclinical systems [1]. A chemical cross-linking mass spectrometry study performed in mitochondria mapped the protein interaction landscape of SS-31 in vitro and found that the interacting proteins were all known cardiolipin binders, falling into groups involved in oxidative phosphorylation and in 2-oxoglutarate metabolic processes, with cross-linked residues frequently proximal to cardiolipin-interacting regions [2]. Work in mitochondria isolated from young and old mouse muscle reported that SS-31 treatment increased ADP sensitivity in aged mitochondria by increasing ADP uptake through the adenine nucleotide translocator, and was accompanied by decreased protein S-glutathionylation, including of ANT [3]. A review of the peptide's pharmacology frames SS-31 as a mitochondria-targeted antioxidant studied for effects on oxidative stress, inflammatory signalling, mitochondrial dynamics and apoptosis across preclinical models [4]. Several cardiac and skeletal muscle models have been reported. In tafazzin-knockdown mice, a genetic animal model of Barth syndrome, mitochondrial respiratory rates were lower than controls, and in vivo SS-31 administration was associated with improved mitochondrial respiratory capacity and supercomplex organisation without altering the monolysocardiolipin/cardiolipin ratio, leading the authors to propose an effect on respiratory chain function rather than on cardiolipin composition directly [5]. In a rat model of heart failure with preserved ejection fraction, skeletal muscle showed reduced cardiolipin levels, contractile dysfunction, titin hyperphosphorylation and fibre atrophy, and elamipretide treatment was reported to change whole-muscle and single-fibre contractile measures, titin phosphorylation and atrophy markers in that animal model [6]. A shotgun proteomics study of old and young mouse hearts found age-associated increases in protein S-glutathionylation that were largely reversed by elamipretide treatment, with partial changes in the phosphoproteome [7]. In cultured rat H9C2 cardiomyoblasts and human induced pluripotent stem cell-derived cardiomyocytes, gamma-irradiation induced senescence-associated beta-galactosidase staining and p16 and p21 expression, and SS-31 exposure in vitro reduced these senescence markers, lowered TNF-alpha, IL-6 and IL-1beta, shifted the BAX/Bcl-2 ratio and reduced mitochondrial reactive oxygen species production [8]. A separate in vitro study conjugated SS-31 with ferrostatin-1 and reported that the combined construct altered viability, iron-handling proteins and ferroptosis markers in H9C2 cells subjected to hypoxia/reoxygenation; the findings describe the conjugate rather than SS-31 alone [9]. Neural models make up a further group. In mice given lipopolysaccharide, elamipretide administration was reported to attenuate mitochondrial dysfunction, oxidative stress, inflammatory markers, hippocampal neuronal apoptosis and dendritic spine loss, with corresponding differences in Morris water maze and contextual fear conditioning performance in that animal model [10]. In a mouse thoracic spinal cord contusion model, SS-31 treatment was associated with altered locomotor and gait measures, reduced lesion pathology, lower cleaved caspase-3 and Bax with higher Bcl-2 early after injury, and changes in astrogliosis and axonal and synaptic remodelling markers at the chronic stage; in parallel in vitro work in oxidatively stressed PC12 cells, SS-31 preserved mitochondrial membrane potential and reduced reactive oxygen species accumulation [11]. In pilocarpine-treated rats, SS-31 was reported to reduce iron and malondialdehyde accumulation in hippocampus, shift Gpx4, Nrf2 and phosphorylated p38 MAPK levels, and alter seizure severity, which the authors interpreted as inhibition of ferroptosis via p38 MAPK signalling in that animal model [12]. Biophysical and cell-culture experiments reported that SS-31 displaced wild-type and N-terminally acetylated alpha-synuclein from negatively charged vesicles, inhibited membrane-induced aggregation, and altered mitochondrial function and viability readouts in alpha-synuclein oligomer-treated neuroblastoma cells in vitro [13]. Not all preclinical results were positive: in an aged, hypertensive mouse model, SS-31 treatment did not significantly reduce cerebral microhaemorrhage burden, and the paper's principal contribution was a machine-learning imaging pipeline for quantifying those lesions [14]. Other organ systems have been examined in rodents. In mice aged to 26 months, a course of SS-31 begun in late age was reported to alter glomerular mitochondrial morphology and glomerulosclerosis, reduce senescence markers, and change markers of parietal epithelial cell activation, podocyte injury and endothelial cell density [15]. In cisplatin-treated mice and HK-2 cells, SS-31 was reported to suppress mitochondrial reactive oxygen species and reduce NLRP3, caspase-1 and IL-1beta expression along with apoptosis in vitro [16]. In bleomycin-treated mice and cultured macrophages, SS-31 was associated with reduced fibrotic and inflammatory readouts and with Nrf2-dependent suppression of NLRP3 inflammasome activation, an effect absent in Nrf2-knockout mice and cells [17]. A nanomedicine study incorporated SS-31 into a liposomal carrier with insulin and reported mitochondrial targeting, reduced reactive oxygen species and altered inflammatory metabolites in hyperosmotic cell models and in a dry eye mouse model, so the findings describe the formulation rather than the free peptide [18]. Two reviews place this body of work in context. One summarises mitochondrial dysfunction in diabetes and Alzheimer's disease and describes SS-31 as a mitochondria-targeted peptide investigated in that setting relative to conventional antioxidants [19]. A narrative review in sports medicine lists SS-31 (elamipretide) among peptides marketed direct to patients without regulatory approval and states that, while many such peptides show tissue-repair or metabolic outcomes in animal models, rigorous human safety data are scarce [20]. The mechanism-focused review likewise notes that clinical trials including PROGRESS-HF, TAZPOWER, MMPOWER-3 and ReCLAIM have been conducted, and that long-term efficacy and safety questions remain open [1]. Researchers evaluating this literature should note that the majority of the mechanistic detail above comes from cells and rodents, that two frequently cited reports test SS-31 as part of a conjugate or nanocarrier rather than alone [9][18], and that at least one aged-animal study reported a null outcome [14].